Advertisement
Screener

ROIVANT SCIENCES LTD. (ROIV) Graph

ROIV Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $1.44M; Research and development $202.02M; Selling, general and administrative (m); Operating expenses $367.83M.
  • 2026-03-31: Revenue $2.52M*; Research and development $198.94M*; Selling, general and administrative (m); Operating expenses $357.51M*.
  • 2025-12-31: Revenue $2.00M; Research and development $165.38M; Selling, general and administrative (m); Operating expenses $341.15M.
  • 2025-09-30: Revenue $1.57M; Research and development $164.57M; Selling, general and administrative (m); Operating expenses $307.80M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ROIV revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$1.44MRevenue$1.44MOperating expenses$367.83MOperating income-$365.99MOther income, net-$2.13MResearch & development$202.02MPre-tax income-$294.56MIncome tax-$3.96M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$1.44M$202.02M(m)$367.83M-$3.96M-$189.84M
2026-03-31$2.52M*$198.94M*(m)$357.51M*$98.35M*$302.99M*
2025-12-31$2.00M$165.38M(m)$341.15M$23.33M-$265.89M
2025-09-30$1.57M$164.57M(m)$307.80M$7.00M-$113.52M
2025-06-30$2.17M$152.92M(m)$287.09M$4.65M-$223.35M
2024-12-31$9.02M$141.59M(m)$283.40M-$25.57M$169.38M
2024-09-30$4.47M$143.07M(m)$346.19M$12.46M-$230.18M
2024-06-30$7.99M$120.51M$148.52M$220.61M$11.96M$95.30M
2024-03-31(m)(m)$169.62M*(m)(m)(m)
2023-12-31$15.56M$108.15M$197.28M$236.52M$22.36M$5.10B
2023-09-30$3.65M$114.79M$164.35M$217.54M$3.24M-$304.33M
2023-06-30$21.62M$125.13M$156.19M$298.04M$1.75M-$291.82M
2022-12-31$17.05M$125.53M$168.26M$395.13M$2.82M-$352.01M
2022-09-30$12.53M$132.00M$157.66M$293.30M$2.17M-$291.59M
2022-06-30$4.32M$135.83M$149.07M$286.63M$4.00M-$331.81M
2021-12-31$24.34M$137.34M$115.53M$270.36M$38.00K-$284.54M
2021-09-30$13.99M$132.10M$437.78M$698.42M$401.00K-$208.48M
2021-06-30$7.74M$78.52M(m)$162.12M$93.00K-$82.18M
2020-12-31$5.75M$202.26M(m)$264.82M-$224.00K-$261.03M
2020-09-30$1.32M$97.41M(m)$157.86M$711.00K-$35.40M
2020-06-30$1.58M$58.73M(m)$116.03M$1.22M-$3.24M

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$3.74M$317.49M(m)$594.90M$11.64M-$336.87M
2024-09-30$12.46M$263.58M(m)$566.80M$24.42M-$134.89M
2023-09-30$8.13M$224.21M$320.55M$431.72M$4.91M-$596.14M
2022-09-30$16.85M$267.82M$306.74M$579.93M$6.16M-$623.40M
2021-09-30$21.72M$210.61M$520.53M$860.54M$494.00K-$290.66M
2020-09-30$2.90M$156.14M(m)$273.89M$1.93M-$38.64M

Revenue and expense 9 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$5.74M$482.87M(m)$936.05M$34.98M-$602.76M
2024-12-31$21.48M$405.18M(m)$850.20M-$1.15M$34.49M
2023-12-31$23.69M$332.35M$517.83M$668.24M$27.28M$4.50B
2022-12-31$33.90M$393.36M$475.00M$975.06M$8.98M-$975.41M
2021-12-31$46.06M$347.96M$636.06M$1.13B$532.00K-$575.20M
2020-12-31$8.65M$358.40M(m)$538.71M$1.71M-$299.67M

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-03-31$8.26M$681.81M(m)$1.29B$133.33M-$299.77M
2025-03-31$29.05M$550.41M(m)$1.14B$48.17M-$171.98M
2024-03-31$32.71M$439.91M$687.44M$884.09M$21.50M$4.35B
2023-03-31$31.53M$454.06M$600.51M$938.29M$4.08M-$1.01B
2022-03-31$55.29M$483.04M$775.03M$1.41B$369.00K-$845.26M
2021-03-31$23.80M$236.63M(m)$1.09B$1.69M-$809.23M

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10